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There is a high prevalence of psychotropic medication use in adults with Intellectual 
Disabilities (ID), often in the absence of psychiatric disorder, also associated with 
challenging behaviour. Previous research has focused on specific sample frames or 
data from primary care providers. There is also a lack of consistency in the definition 




We adopted a total population sampling method. Medication data on 265 adults with 
ID were classified according to the Anatomical Therapeutic Chemical classification 
system. The Behavior Problems Inventory – short form classified challenging 
behaviours. We examined the association between challenging behaviour and the 
use of psychotropic medication, and whether any association would still be present 
after accounting for sociodemographic and clinical characteristics. 
 Results  
 
70.57% of adults with ID were prescribed at least one class of any medication (mean 
per person = 2.62; range 0-14). Psychotropic medications were used by 37.73% of 
participants with antipsychotics the commonest type used by 21.89% of individuals. 
Polypharmacy and high dosages were common. Generalised Linear Models 
indicated significant associations between psychotropic medication and the presence 
of a psychiatric diagnosis, challenging behaviour, older age and type of residence. 




The use of a total population sample identified via multiple routes is less likely to 
overestimate prevalence rates of medication use. Current challenging behaviour was 
a predictor of medication use after controlling for other variables. Data indicate that 
there may be differences in prescribing patterns associated with different 
topographies of challenging behaviours. 
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Psychotropic medication, and in particular antipsychotic medication, is overused in 
people with intellectual disabilities (ID) (Deb & Fraser, 1994; Sheehan et al. 2015). 
Studies have reported varied prevalence and patterns of prescribing. For example, 
UK estimates vary from 49% (Sheehan et al. 2015) to 89% (Deb et al. 2014) with 
some variation subject to residence or setting of the sample cohort (Robertson et al. 
2000; Tsiouris et al. 2013). Antipsychotics have been reported to be the most 
common type of medication prescribed to individuals with ID (Holden & Gitlesen, 
2004; Deb & Unwin, 2007; Matson & Neal, 2009; Singh & Matson, 2009; Henderson 
et al. 2015; Sheehan et al. 2015). Up to 62% of adults with ID who receive 
psychotropic medication receive multiple psychotropic medications (Lott et al. 2004) 
often in high dosages (Cullen, 1999; McGillivary & McCabe, 2004; Deb et al. 2009; 
Taylor, 2010). A high prevalence of psychiatric problems in adults with ID may 
explain some increased medication use (Chaplin, 2004; Cooper et al. 2007; Morgan 
et al. 2008; Buckles et al. 2013). However, prescribing rates are typically higher than 
reported rates of mental health problems (Henderson et al. 2015; Sheehan et al. 
2015) and prescribing is also associated with the presence of challenging behaviour 
(Gothelf et al. 2008; Matson & Neal, 2009; Henderson et al. 2015; Sheehan et al. 
2015). 
In studies that have used convenience or small samples recruited from clinical 
services, estimates of the prevalence of the use of psychotropic medication have 
been high. For example, in a community based sample of adults with ID and 
aggressive behaviour, from ten psychiatric clinics in the West Midlands, UK, 89% 
were prescribed psychotropic medication (Deb et al. 2014). Similarly, 72% of adults 
with ID at a Psychiatry Department in Salford, UK, were prescribed antipsychotics 
(Griffiths et al. 2012). Data from such samples are likely to be associated with a 
range of biases and total population or population representative samples are 
needed. Henderson et al. (2015) focused on a prospective cohort sample of 1023 
adults aged >16 years with ID known to local services including primary care 
(general practitioners - GPs) in Scotland. Sheehan et al. (2015) identified 32306 
adults aged >18 years with ID from 3.7 million active patients on The Health 
Improvement Network (THIN) where records from 571 General Practices were 
examined. Henderson et al. (2015) found a 49.1% prevalence rate of psychotropic 
medication use with a prevalence rate of antipsychotic drug use of 23.2%. Similarly, 
Sheehan et al. (2015) found a 49% prevalence of psychotropic medication use with 
21% of participants prescribed antipsychotic medication. These studies used 
population-based samples, but identified their participants from primary care 
services.  
Some studies have found that adults with challenging behaviour are 
prescribed more psychotropic medications than those without challenging behaviour 
(Holden & Gitlesen, 2003; Aman & Ramadan, 2007; Crossley & Withers, 2009; Doan 
et al. 2013; Scheifes et al. 2015). In the Henderson et al. (2015) study, 32% of those 
prescribed antipsychotics had no mental health problems at the time of assessment. 
Sheehan et al. (2015) reported that 47% of participants with a record of challenging 
behaviour received antipsychotics but only 12% had a record of mental illness. There 
remains no convincing evidence of positive treatment effects of these medications on 
challenging behaviour (Emerson & Baines, 2010; Tsiouris, 2010; Paton et al. 2011; 
Wilner, 2014). The underlying aetiological factors for challenging behaviour are 
complex and varied (Hastings et al. 2013) so treatment with medication alone is 
unlikely to resolve the issue. Under current UK best practice guidelines (NICE, 2015; 
RCP, 2016) if adults with ID and challenging behaviour have no evidence of mental 
illness then there may be no role for prescribing, other than in the very short term to 
address risk whilst other psycho-social interventions are implemented. 
Socio-demographic factors associated with higher prevalence rates of 
psychotropic medication are male gender (McGillivray & McCabe, 2006; Delafon et 
al. 2013; Doan et al. 2014) and older age (Holden & Gitlesen, 2004; Singh & Matson,  
2009; Deb et al. 2014; Sheehan et al. 2015). Kiernan et al. (1995) found different 
prevalence rates in different districts of the UK and hypothesised that this may be 
due to different organisation in psychiatric services for people with ID. Variation in 
prevalence rates by residential setting has also been identified with highest 
prevalence rates in hospitals, lower in community residential services, and lowest in 
family homes (Clarke et al. 1990; Kiernan et al. 1995; Robertson et al. 2000; Tsiouris 
et al. 2013).  
Further research is thus required for several reasons. First, obtaining accurate 
prevalence rates of psychotropic drug use has been problematic given many existing 
studies have focused on small, highly selective convenience samples with a lack of 
population wide estimates (Sheehan et al. 2015). The number of population-based 
studies is small with participants recruited predominantly from primary care. One of 
the limitations of the Sheehan et al. (2015) study was the potential under-recording 
by GPs of people with mild ID. This may have overestimated the prevalence of 
prescribing given potentially lower levels of challenging behaviour (Bowring et al. 
2016) and psychiatric problems (Whitaker & Read, 2006) in this sub-group. One 
disadvantage of using data from primary care is the lack of reliable and consistent 
identification of adults with an ID. Second, there has been variation in results due to 
a lack of standardised medication rating systems, preventing comparisons between 
studies. For example, some researchers have included antiepileptics for epilepsy as 
psychotropic medications (Holden & Gitlesen, 2004; Henderson et al. 2015), 
whereas other researchers have classed them as somatic medication (Scheifes et al. 
2013; Doan et al. 2014).Third, researchers have used varied definitions of 
challenging behaviour to examine its putative association with medication use. 
Sheehan et al. (2015) used a 200 long list of behaviours, including sleep 
disturbance, which primary care providers coded against records. This system was 
not externally validated, it was not clear if all behaviours would be reported to GPs, 
and did not identify if the problem was historical or current. Sheehan et al. (2015) 
reported that 36% of participants had a record of challenging behaviour with the 
majority of codes featuring generic labels such as  ‘behaviour problem’ or ‘behaviour 
disorder’ with few specific topographical codes used. This rate of challenging 
behaviour is considerably higher than reported in other recent population studies 
(Bowring et al. 2016: 18.1%; Jones et al. 2008: 18.7%-22.5%; Lundqvist, 2013: 
18.7%). Behaviour may be more accurately assessed through a direct individual 
assessment utilising a psychometrically evaluated behaviour rating scale with clear 
definitions of what constitutes challenging behaviour taking into account temporal 
and intensity factors.  
The main aim of the present study was to address these limitations in existing 
studies by investigating the prevalence of medication use, particularly psychotropic 
medication, in the total administrative population of adults with ID (identified through 
multiple methods) in Jersey, Channel Islands. We determined the prevalence of 
psychotropic medication using an internationally recognised coding system (the 
World Health Organisation Anatomic Therapeutic Classification Scheme - WHO, 
2014; WHOCC – ATC/DDD, 2014) and examined associations with challenging 
behaviour, and specific sub-types of challenging behaviour, identified by a rating tool 
with good psychometric properties (the Behavior Problems Inventory – short form; 
Rojahn et al. 2012a). We also explored whether any association between medication 
prescription and challenging behaviour would be present after accounting for other 






Participants were 265 persons ≥ 18 years of age administratively defined as having 
ID (i.e., who were receiving, or had received, support from services in Jersey). 
Participants were identified from multiple sources including the Health and Social 
Services (H&SS) administrative database, in Jersey, FACE (Functional Analysis of 
Care Environments, http://www.face.eu.com). FACE is a database used by the local 
community multi-disciplinary ID service which includes social work, occupational 
therapy, community nursing, positive behaviour support service and physiotherapy. 
Records were cross-referenced with current Education Department Record of 
Needs, and records of individuals maintained by local service providers from the 
voluntary sector and employment support services. The population ascertainment 
process and more detail on the procedure is provided in a previous paper (Bowring 
et al. 2016).  
This identified 311 potential participants. Surveys were completed with 265 
participants which is equivalent to 97% of eligible and traceable participants (N=274; 
9 declined consent) or 85% of eligible people (N=311; 11 were traced but did not 
reciprocate contact, and we were unable to trace 26). Informed consent was 
obtained from 162 adults. For 103 adults who did not have capacity to provide 
independent consent consultees gave consent. Given that surveys were completed 
on 85% of eligible participants results are a robust representation of the Jersey 




The study was approved by XXX University ethics committee, and by the States of 
Jersey, Health and Social Services ethics committee. The authors assert that all 
procedures contributing to this work comply with the ethical standards of the relevant 
national and institutional committees on human experimentation and with the 
Helsinki Declaration of 1975, as revised in 2008.  
Researchers completed two surveys for each participant in face-to-face 
meetings with a proxy informant. Informants were either family members or key 
workers within a supporting organisation. Informants were judged to be in a good 
position to provide information about the participant if they had a minimum of regular 
weekly contact and had known the participant for at least one year. All data were 




1. Medication data  
 
The first survey tool was adapted from the Individual Schedule of the Challenging 
Behaviour Survey (Alborz et al. 1994) and the Wessex Scale (Kushlick et al. 1973; 
Palmer & Jenkins, 1982) to collect socio-demographic information and clinical 
characteristics including medication use. Definitions for degree of ID were taken from 
the UK Department for Work and Pensions Guidance (2012). This definition 
categorises degree of ID based on IQ score (mild: 50-69; Moderate: 35-49; severe: 
20-34; profound: less than 20) and describes typical daily living skills and support 
needs associated with each category. Whilst there was a reliance on proxy 
information, all responses were checked where possible against records stored on 
FACE. 
 Medication data collected included name of medication and corresponding 
dosage. For adults living in paid and congregate care settings (n=132) data were 
taken directly from individual Medication Administration Record (MAR). For adults 
who lived independently or with family, medication use data were provided by proxy 
informants (n=133).  
The system for coding medication use (WHO, 2014; WHOCC – ATC/DDD, 
2014) has been used in other studies of medication use in individuals with ID 
(Scheifes et al. 2013; Doan et al. 2014). The ATC system groups medications into 14 
categories according to the organs or system on which they act or their chemical, 
pharmacological or therapeutic characteristics (Doan et al. 2014). Medication was 
independently coded by an Intellectual Disability Nurse, with research experience, 
who was an independent and supplementary prescriber (v300 Qualification). 
Psychotropic medications were defined as medical agents for the nervous system, 
excluding analgesics and antiepileptics prescribed for epilepsy (Doan et al. 2014). 
Psychotropic medications included anticholinergic agents, antipsychotics, anxiolytics, 
hypnotics and sedatives, antidepressants, psychostimulants and antiepileptics used 
as mood stabilisers. 
There were several cases where there were different codes for particular 
medicines depending on their purpose of pharmacology. In 11 cases the research 
team had to return to proxy informants, or the health service database (FACE), to 
establish medical history and the pharmacological purpose of the medicine. Of the 
68 people who were using antiepileptics, 15 did not have a diagnosis of epilepsy or 
history of seizures when checked against the demographic data. Further research 
established 7 were prescribed antiepileptics as mood stabilisers so were classified in 
the psychotropic drug category as per previous studies (Scheifes et al. 2013). The 
other 7 people were prescribed antiepileptics for absence seizures (and suspected 
epilepsy) or pain and were categorised under the appropriate somatic label. 
For each medication, the ATC also provides a defined daily dose (DDD) which 
is in effect an average daily dosage for its main indication. Dosage was investigated 
for medication which affected the nervous system (N-coded) which included 
psychotropic medication. We recorded dosage against the listed DDD as below the 
DDD, equivalent to the DDD, or above the DDD. There were 3 medication entries 
within the nervous system category which researchers could not code due to the 
individual way dosage is calculated (Lithium x2) and due to brand differences 
(Nicotine patches x1). 
The numbers of people prescribed PRN (as required) medication was very 
small (N=15) and so we did not include this as an analysis variable (cf. Schiefes et 
al. 2013; Sheehan et al. 2015).  
All coded medication data were then independently checked by another 
researcher. There were two (from 694) data entry errors, which were amended. 
Prevalence was then calculated for all medications. The independent coder then 
categorised all medication within the four digit ATC code to create a table of 
prevalence according to the class of the medication (see Table 2). 
 
2. Challenging behaviour data 
 
Researchers also completed the Behavior Problems Inventory - short form (BPI-S) 
(Rojahn et al. 2012ab; Mascitelli et al. 2015) to measure challenging behaviour 
during the previous six months as reported by proxy informants. BPI-S data were 
coded against the following definition (Bowring et al. 2016): 
a) SIB: any item of self-injurious behaviour is “challenging” if either it is rated as 
severe and occurs at least weekly, or is rated as moderate but occurs at least 
daily. Any other occurrence of behaviour is not rated as challenging. 
b) ADB: any item of aggressive destructive behaviour is “challenging” if either it 
is rated as severe and occurs at least weekly, or is rated as moderate but 
occurs at least daily. Any other occurrence of behaviour is not rated as 
challenging. 
c) SB: any item of stereotyped behaviour is “challenging” if it occurs at the 
highest rated frequency (hourly). Any other occurrence of behaviour is not 
rated as challenging. 
d) CB: Overall challenging behaviour is defined by the presence of a least one 
behaviour defined as “challenging” in the above categories. 
The overall prevalence of challenging behaviour was 18.1% (95% CI: 13.94%-
23.19%; n=48), self-injurious behaviour was 7.5% (95% CI: 4.94%-11.37%; n=20), 
aggressive and destructive behaviour 8.3% (95% CI: 5.54%-12.25%; n=22), and 
stereotyped behaviour 10.9% (95% CI: 7.73%-15.27%; n=29) (Bowring et al. 2016).  
 Statistical Analysis 
 
Data were analysed using Statistical Package for the Social Sciences Version 
21 (SPSS, Inc., Chicago, Il, USA). Descriptive statistics were used to summarise the 
overall prevalence of medication use in the sample. We then investigated the 
association between challenging behaviour (total challenging behaviour, aggressive 
and destructive behaviour, self-injury and stereotypy) and medication using Chi 
Square associations, additionally estimating unadjusted Relative Risks (RR). Finally, 
we adjusted for other variables using multivariable Generalised Linear Models (GLM) 






Table 1 summarises participant characteristics. Of the 265 participants 50.6% 
(n=134) were male and 49.4% (n=131) female with a mean age of 41.44 (range 18-
85). The majority lived in either congregate care (40.8%) or with family (34.3%). Over 
a quarter of adults (26.4%) had a psychiatric condition. 
 




+++INSERT TABLE 2+++ 
 
Table 2 shows the prevalence of medication use within this sample. A total of 
70.57% (n=187) of adults with ID were prescribed at least one medication 
(mean=2.62; range 0-14). Under the ATC system the largest group of medications 
used were those coded to treat the nervous system used by 52.07% (n=138), 
followed by those for alimentary tract and metabolism used by 31.32% (n=83), 
followed by drugs for the cardiovascular system used by 15.69% (n=40).  
Within the total sample 37.73% (n=100; mean=.68; range 0-5) used a 
psychotropic medication. The largest group of psychotropic medications used were 
antipsychotic medications used by 21.89% (n=58; mean=.27; range 0-3). Most 
commonly used were second generation (atypical) antipsychotics used by 15.09% 
(n=40). Of these the most common medications were Risperidone (n=16) and 
Olanzapine (n=13). Of the first generation (typical) antipsychotics used by 7.92% 
(n=21), the most common drug used was Haloperidol (n=10). The second largest 
group of psychotropic medications was antidepressants used by 17.38% (n=46; 
mean number=.18; range 0-2). The majority of these were selective serotonin 
reuptake inhibitors (SSRI) antidepressants used by 12.83% (n=34). The most 
common SSRI drugs used were Citalopram (n=10), Paroxetine (n=7) and Fluoxetine 
(n=6). 
  
Dosage and polypharmacy 
 
Nearly one-third of participants who were prescribed medication for the nervous 
system were prescribed at a level above the DDD: 30.43% (n=42) used at least one 
medication above the DDD (35 people took one medication above DDD, 6 people 2 
medications above DDD, 1 person 3 medications above DDD).  
Among those prescribed medication for the nervous system (n=138) 41.31% 
were prescribed just one medication, while 58.69% were prescribed 2+ medications 
(mean =3.20; range 2-5). Polypharmacy was also common with psychotropic 
medication. Among those prescribed psychotropic medication (n=100), 51% were 
prescribed just one medication, while 49% were prescribed 2+ medications 
(mean=3.69; range 2-5). 
 




+++INSERT TABLE 3+++ 
 
Chi-square tests were used to explore the association between challenging 
behaviour (total challenging behaviour, aggressive and destructive behaviour, self-
injury and stereotypy) and medication use. Table 3 summarises these associations 
by detailing the percentage in the challenging behaviour and no challenging 
behaviour groups prescribed medication. Where associations were statistically 
significant at p<.05 we supplemented the chi-square results with a Relative Risk 
(RR) described below. 
Adults with challenging behaviour were nearly twice as likely to be prescribed 
psychotropic medication compared to adults who did not present challenging 
behaviour (RR=1.921, 95% CI: 1.328 to 2.781). Similarly, adults who displayed 
aggressive and destructive behaviour were nearly two times more likely to have 
been prescribed psychotropic medication (RR=1.891; 95% CI: 1.207 to 2.965). The 
adults with self-injurious behaviour were more than two and a half times as likely to 
have  psychotropic medications prescribed (RR=2.606; 95% CI=1.741 to 3.902). 
There was no significant association between stereotyped behaviour and 
psychotropic medication use. 
Adults with challenging behaviour were nearly three times as likely to have 
been prescribed antipsychotic medication compared with adults who did not present 
challenging behaviour (RR=2.99; 95%CI: 1.524 to 5.869). Similarly, adults with 
stereotyped behaviour were nearly two and a half times as likely to use antipsychotic 
medication (RR=2.457; 95%CI: 1.087 to 5.553). Adults with self-injurious behaviour 
were more than four times as likely to use antipsychotic medication (RR=4.104; 
95%CI: 1.617 to 10.418). There was no association between aggressive destructive 
behaviour and antipsychotic drug use.  
There was no association between antidepressant medication use and any 
topography of challenging behaviour. 
 
Multivariate analysis of the challenging behaviour-psychotropic medication 
association 
 
In the final analyses, we wanted to explore whether the associations between 
challenging behaviour and medication use remained after accounting for potential 
correlates of medication use. To identify correlates, we first ran a simple generalised 
linear model (GLM) to obtain an unadjusted RR between the potential correlate 
(sociodemographic and other clinical characteristics) and the use of medication 
variables. Variables considered were largely those identified in previous studies such 
as psychiatric diagnosis, age, gender, type of residence (living in paid/congregate 
care versus other), degree of ID (severe/profound versus mild/moderate), low 
communication skills (non-verbal or no clear speech and limited receptive 
understanding) and sensory impairments (sight or hearing impairment). All correlates 
significantly associated with medication use were then fitted into a multivariable GLM 
to examine all potentially relevant correlates alongside challenging behaviour. 
GLMs were used to explore the association with the number of psychotropic 
medications used (0,1,2,3+) fitted to follow a Poisson distribution with robust 
standard errors (Knoll et al. 2012). For a number of antipsychotic medications 
(defined as 0 and 1+) we fitted a logistic GLM. Results are presented in tables 4 and 
5. 
 
+++INSERT TABLE 4+++ 
+++INSERT TABLE 5+++ 
 
Results from GLM Poisson regression models showed that those with a 
psychiatric diagnosis had a 4.22 RR (95% CI 3.007 to 5.92; p<.001) of being 
prescribed psychotropic medication (Table 4). Those living in paid or congregate 
care had a 2.015 RR (95% CI 1.378 to 2.946; p<.001); those who presented 
challenging behaviour a 1.921 RR (95% CI 1.328 to 2.781; p<.001); adults with a 
severe profound ID a 1.475 RR (95% CI 1.009 to 2.155; p=.045); and (older) age 
gave a 1.034 RR (95% CI 1.025 to 1.044; p<.001). There were no significant 
associations between gender, sensory impairment or low communication skills and 
the use of psychotropic medication. When all significantly associated variables were 
entered in the GLM model together (Table 5), severe-profound ID was no longer 
significantly associated with psychotropic use. Significant correlates remaining 
included psychiatric disorder (RR=3.725; 95% CI 2.68 to 5.178; p<.001), challenging 
behaviour (RR=1.565; 95% CI 1.074 to 2.282; p=.02), living in paid/congregate care 
(RR=1.542; 95% CI 1.082 to 2.196; p=.016) and (older) age (RR=1.023; 95% CI 
1.013 to 1.034; p<.001). 
Using GLM loglink regression models we found that those with a psychiatric 
diagnosis had a 7.478 RR (95% CI 3.945 to 14.174; p<.001) of using antipsychotic 
medication (Table 4). Those who presented with challenging behaviour had a 2.99 
RR (95% CI 1.524 to 5.869; p=.001); those living in paid / congregate care a 2.516 
RR (95% CI 1.363 to 4.644; p=.003); males had a 2.42 RR (95% CI 1.311 to 4.466; 
p=.005); those with a  severe/profound ID a 2.099 RR (95% CI 1.096 to 4.019; 
p=.025); and (older) age a 1.05 RR (95% CI 1.03 to 1.071; p<.001). There was no 
significant association between sensory impairments and low communication skills 
and antipsychotic medication use. When all significant correlates were entered into 
the model together (Table 5), living in paid/congregate care and severe/profound ID 
were no longer significant. Significant correlates remaining were psychiatric disorder 
(RR=9.124; 95% CI 4.151 to 20.058; p<.001), male gender (RR=3.35; 95% CI 1.573 
to 7.134; p=.002), challenging behaviour (RR=2.968; 95% CI 1.131 to 7.79; p=.027) 




Among the total administrative population of adults with ID in Jersey, nearly 4 in 10 
were in receipt of at least one psychotropic medication (37.73%, n=100) and  
30.43%, (n=42) were prescribed a medication which acts on the nervous system 
above the indicated daily dose. Nearly half of all adults prescribed psychotropic 
medications (49%, n=49) were in receipt of more than one of these medications. 
Thus, the use of psychotropic medication, at high doses and polypharmacy were 
common supporting previous evidence (Deb et al. 2014; Henderson et al. 2015; 
Sheehan et al. 2015). 
The most prevalent group of medications was antipsychotics, prescribed to 
21.89% of people. This confirms the preference for this type of medication by 
prescribers as seen in other studies (Holden & Gitlesen, 2004; Deb & Unwin, 2007; 
Matson & Neal, 2009; Singh & Matson, 2009). Second generation antipsychotics 
were used by 15.09% of the sample which confirms a shift in prescribing patterns to 
second generation antipsychotics and SSRIs (Spreat et al. 2004; Matson & Neal, 
2009; Paton et al. 2011). 
The prevalence of psychotropic drug use is lower in our sample than those 
reported from other recent studies in the UK (e.g. Henderson et al. 2015, 49.1%; 
Sheehan et al. 2015, 49%). There are a number of potential reasons for this. First, 
one strength of this population study was that it did not recruit from a particular 
clinical route such as participants in contact with general practitioners and 
psychiatrists (e.g. Henderson et al. 2015; Sheehan et al. 2015). Sheehan et al. 
(2015) indicate they may have over-estimated prevalence of prescribing due to 
difficulties identifying adults with mild ID from GP records. The total population 
ascertainment process in this study used multiple routes. There may be potentially 
lower prevalence estimates in studies that consider total population samples and not 
just primary care records or records from specialised challenging behaviour, 
residential, or hospital services. In a county in Norway, adults with ID known to 
services (N=300) and living in the community, had a similar prevalence of 
psychotropic prescribing (37.4%) to the current study (Holden & Gitlesen, 2004) 
Second, our total population study did not recruit from one specific clinical 
setting like other studies with high prevalence rates (e.g. Griffiths et al. 2012, 72%; 
Deb et al. 2014, 89%) but from multiple routes. We found prevalence of 
antipsychotics by residence was only 11% for those residing in family homes, 21.4% 
in independent living and much higher at 29.5% in paid/congregate care. Studies 
that have considered differing prescribing patterns by including community samples 
may lead to lower prevalence estimates.  
Third, previous studies have identified regional variations in prevalence rates 
between districts of origins in the UK (Kiernan et al. 1995). This has been explained 
by the fact that prescribing professionals, practices and samples will vary by region. 
There appears to be less use of certain medications in Jersey. Sheehan et al. (2015) 
reported a 21% prevalence of antipsychotics and 20% prevalence of antidepressants 
which was similar to the present sample (21.89% and 17.36%), but a higher 
prevalence of mood stabilisers (20%) and anxiolytics/hypnotics (22%) compared to 
the present sample (2.64% and 10.57%). The Jersey General Hospital Formulary 
(States of Jersey, 2016) lists medications licenced to be prescribed in Jersey. This 
may detail a slightly different set of medications to other authorities/countries and 
identifies some medications that GPs cannot prescribe.  
In Jersey, all adults with ID and challenging behaviour are open to the ID 
psychiatrist. Some evidence has suggested a reduced level of prescribing from 
psychiatrists compared to GPs (Holden & Gitlesen, 2004). We found that 39.7% of 
adults with ID in receipt of antipsychotic medication did not have a psychiatric 
disorder. This rate is lower than that reported in other recent studies (50-71%: 
Tsiouris, 2010, Paton et al. 2011; Marston et al. 2014; Sheehan et al. 2015). This 
may have contributed to lower rates of prescribing. Further investigations are 
required into regional variations and what influences prescribing patterns of 
individual medications at a prescriber level.  
Our data also suggested that psychotropic medication prescribed in the 
absence of a psychiatric diagnosis may be related to the presence of challenging 
behaviour. Ascertainment of the presence of challenging behaviour was a strength of 
the current study through the BPI-S. Our data extended previous findings (Brylewski 
& Duggan, 2004; Tsiouris, 2010; Henderson et al. 2015; Sheehan et al. 2015) by 
indicating different patterns of association with specific topographies of challenging 
behaviour. Psychotropic medication use was associated with aggressive/destructive 
behaviour and self-injurious behaviour, but not stereotyped behaviour. Antipsychotic 
medication use was associated with self-injurious behaviour and stereotyped 
behaviour, but not aggressive/destructive behaviour. Adults with SIB in particular 
may be a priority for psychosocial interventions and medication reviews. It is of 
interest that antipsychotic use was associated with behaviours that could be 
considered inner-directed (self-injury and stereotypy), but not outward-directed such 
as aggression/destruction. In the presence of aggression/destruction the relative risk 
of using hypnotics/sedatives was over 200% and 700% for using antiepileptics as 
mood stabilisers. Mood stabilisers for aggression have been documented in other 
studies (Deb et al. 2014; Wilner, 2014: Tsiouris et al. 2015).  Overall, our data 
indicate that differences in prescribing patterns may be associated with specific 
challenging behaviours, or the features associated with those behaviours which 
requires further investigation.   
Factors other than challenging behaviour and psychiatric diagnosis were also 
independently associated with medication use. Psychotropic medication use was 
additionally associated with living in paid/congregate care and increased age. 
Antipsychotic medication was similarly associated with increased age and also male 
gender. Associations between psychotropic medication use, older age, and type of 
residence have been seen consistently in other studies (Aman et al. 1995; Kiernan et 
al. 1995; Singh et al. 1997; Robertson et al. 2000; Holden & Gitlesen, 2004; 
Sheehan et al. 2015). The increased likelihood of receiving antipsychotic medication 
for males compared to females has also been reported in other studies and requires 
further exploration to consider why this is (McGillivray & McCabe, 2006; Delafon et 
al. 2013; Doan et al. 2014).  
A limitation of the present study is that findings apply only to the 
administratively defined ID population in Jersey while there may also be adults with 
ID < 70 not known to services who were not included. However, findings from this 
study are likely useful in practice since specialised support (such as for medication 
reviews) might be best planned on the basis of a population of people with ID 
already known to services. The sample size was also relatively small compared to 
other recent studies. A second limitation was the reliance on proxy informants to 
report medication use for those living in family or independent settings (133 
participants) where there is a possibility of misreporting as these informants are not 
clinically trained. However, potential inaccuracy was limited as proxy informants 
often showed researchers the medication with listed name and dosage; where they 
were unsure they made further enquiries and researchers contacted them again. 
Follow up checks were also made on the FACE database as initial assessments, 
care plans and nursing plans listed on FACE usually contained information on 
medication use. PRN medication use was rare, but future studies with larger 
samples could also consider separate analysis of these medications. 
 
Implications for policy and practice 
 
Despite the lower prevalence in this sample, prescribing levels of psychotropic 
medication are still too high and often related to challenging behaviour with no 
evidence this practice is effective (Matson & Neal, 2009). Studies on withdrawing 
medication suggest many adults with ID can do so successfully (Ahmed et al. 2000). 
Health organisations should complete audits to ascertain psychotropic prescribing 
levels and identify adults requiring a psychiatric review of their medication. The 
involvement of specialist prescribers, rather than GPs, is essential as there is 
evidence prescribing rates are lower where psychiatrists lead prescribing (Holden & 
Gitlesen, 2004).  
Although requiring future replication, we found that different topographies of 
behaviour related to different patterns of prescribing, with those with SIB being a 
particularly high risk group. Efforts should be made to reduce prescribing in high risk 
populations by prioritising them for medication reviews (RCP, 2016) and alternative 
psychosocial interventions.  
We also found that general medication use is high in adults with ID (for 
example, 31.32% were in receipt of medication for the alimentary tract and 
metabolism) and future research needs to investigate the high prevalence of all 
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Table 1. Baseline Characteristics of the study population (N=265) 
Characteristic N (%) 
Mean age  41.44 years (SD: 16.278) 
Gender  Male: 134 (50.6%) 
Female: 131 (49.4%) 




Time in setting  
Congregate care: 108 (40.8%) 
Paid carer: 24 (9.1%) 
Family carer: 91 (34.3%) 
Independent living: 42 (15.8%) 
Less than 1 year: 32 (12.1%) 
1-5 years: 60 (22.6%) 
6-10 years: 62 (23.4%) 
11-20 years: 53 (20%) 
21 years plus: 58 (21.9%) 
Degree of intellectual disability  Profound: 26 (9.8%) 
Severe: 32 (12.1%) 
Moderate: 83 (31.3%) 
Mild: 124 (46.8%) 
Other diagnoses (include)  Autism: 31 
Down Syndrome: 36 
Cerebral Palsy: 15 
ADHD: 2 
Fragile X: 2 
Soto syndrome: 2 
Other: 11 
Daytime engagement  Paid work: 37 (14%) 
Voluntary work: 39 (14.7%) 
Vocational training: 22 (8.3%) 
Education: 5 (1.9%) 
Day service: 60 (22.6%) 
No daytime engagement: 102 (38.5%) 
Epilepsy  57 (21.5%) 
Psychiatric condition  
 
70 (26.4%) including: 
Depression: 31 (11.7%) 
Schizophrenia: 18 (6.8%) 
Affective Disorder 10 (3.8%) 
Psychotic condition 8 (3%) 
























 Table 2.The prevalence of medication use in the study population by ATC category 
(N=265). 
ATC section Category ATC  four digit category N = Number of participants 
(range) 
% of participants 
 
N - Nervous System  138 (0-5) 52.07 
 
 Psychotropic Medication 100 (0-5) 37.73 
 Anticholinergic agents N04A 25 (0-1) 9.43 
 AntiPsychotic N05A 58 (0-3) 21.89 
    First generation 
Antipsychotic  
21 (0-3) 7.92 
    Second generation 
Antipsychotic 
40 (0-1) 15.09 
    Drugs for mania and 
hypomania Anti-psychotic 
5 (0-1) 1.89 
 Anxiolytics N05B 11 (0-1) 4.15 
 Hypnotics and sedatives 
N05C 
17 (0-1) 6.42 
 AntiDepressants N06A 46 (0-2) 17.36 
    SSRI AntiDepressants 34 (0-2) 12.83 
    Tricyclic Antidepressants 5 (0-1) 1.89 
    Other Antidepressants 9 (0-1) 3.40 
 Psychostimulants N06B 1 (0-1) 0.38 
 Antiepileptic’s as Mood 
stabilisers N03A 
7 (0-1) 2.64 
 
 Analgesia N02A/B/C 14 (0-2) 5.28 
 Antiepileptics for nerve pain 
N03A 
3 (0-1) 1.13 
 Antiepileptics for epilepsy 
N03A 
57 (0-4) 21.51 
 Dopaminergic agents N04B 2 (0-2) 0.75 
 Anti-dementia drugs N06D 3 (0-1) 1.13 
 Drugs used in Nicotine 
dependence N07B 
1 (0-1) 0.38 
A - Alimentary tract and 
metabolism  
 83 (0-5) 31.32 
B- Blood and blood forming 
organs  
 26 (0-3) 9.81 
C- Cardiovascular system   40 (0-4) 15.09 
D - Dermatologicals   16 (0-2) 6.04 
G - Genito-urinary system 
and sex hormones  
 30 (0-2) 11.32 
H - Systemic hormonal 
preparations 
 24 (0-2) 9.06 
J - Antiinfectives for systemic 
use 
 16 (0-1) 6.04 
L - Antineoplastic and 
immunomodulating agents  
 2 (0-1) 0.75 
M - Musculo-skeletal system  20 (0-2) 7.55 
R - Respiratory System  24 (0-4) 9.06 
S - Sensory organs   5 (0-1) 1.89 
V - Various   6 (0-1) 2.26 
 
 Total medication use 187 (0-14) 70.6 





















56.3 39.6 18.8 
No Challenging 
behaviour (%): 
33.6 18 17.1 












35.4 20.6 16.5 








70 50 25 
No Self-injurious 
Behaviour (%): 
35.1 19.6 16.7 








48.3 37.9 6.9 
No Stereotypical 
Behaviour (%): 
36.4 19.9 18.6 

































Table 4. Association of medication use with sociodemographic and clinical 
characteristics: Unadjusted Relative Risk. 
Psychotropic medication 
 Unadjusted RR (95% CI; p=) 
Challenging behaviour (N=48) 1.921 (1.328 to 2.781; p=.001) 
Psychiatric disorder (N=70) 4.22 (3.007 to 5.92; p<.001)  
Male gender (N=134) 1.312 (.91 to 1.892; p=.145) 
Paid / congregate care (N=132) 2.015 (1.378 to 2.946; p<.001) 
Severe / profound ID (N=58) 1.475 (1.009 to 2.155; p=.045) 
Age (N=265) 1.034 (1.025 to 1.044; p<.001) 
Sensory impairment (N=38) 1.134 (.696 to 1.848; p=.615) 
Low communication skills (N=33) .984 (.581 to 1.668; p=.953) 
Antipsychotic medication 
 Unadjusted RR (95% CI; p=) 
Challenging behaviour (N=48) 2.99 (1.524 to 5.869; p=.001) 
Psychiatric disorder (N=70) 7.478 (3.945 to 14.174; p<.001) 
Male gender (N=134) 2.42 (1.311 to 4.466; p=.005) 
Paid / congregate care (N=132) 2.516 (1.363 to 4.644; p=.003) 
Severe / profound ID (N=58) 2.099 (1.096 to 4.019; p=.025) 
Age (N=265) 1.05 (1.03 to 1.071; p<.001) 
Sensory impairment (N=38) 1.127 (.501 to 2.539; p=.772) 




Table 5. Association of medication use with sociodemographic and clinical 
characteristics: Adjusted Relative Risk. 
Psychotropic medication 
 Adjusted RR (95% CI; p=) 
Challenging behaviour (N=48) 1.565 (1.074 to 2.282; p=.02) 
Psychiatric disorder (N=70) 3.725 (2.68 to 5.178; p<.001) 
Paid / congregate care (N=132) 1.542 (1.082 to 2.196; p=.016) 
Severe / profound ID (N=58) .926 (.627 to 1.367; p=.699) 
Age (N=265) 1.023 (1.013 to 1.034; p<.001) 
Antipsychotic medication 
 Adjusted RR (95% CI; p=) 
Challenging behaviour (N=48) 2.968 (1.131 to 7.79; p=.027) 
Psychiatric disorder (N=70) 9.124 (4.151 to 20.058; p<.001) 
Male gender (N=134) 3.35 (1.573 to 7.134; p=.002) 
Paid / congregate care (N=132) 1.096 (.774 to 4.698; p=.161) 
Severe / profound ID (N=58) 1.131 (.427 to 2.998; p=.804) 
Age (N=265) 1.043 (1.018 to 1.069; p=.001) 
 
